As first reported by Focus Taiwan, Taipei Veterans General Hospital (TVGH) has introduced BrainProbe, the world’s first AI-powered platform for assisting in the diagnosis of schizophrenia. Developed by TVGH’s Medical AI Development Center, BrainProbe analyzes MRI data using deep learning algorithms to identify patterns of brain degeneration associated with the condition. With an accuracy rate of 91.7%, the system offers a significant leap forward in a field long challenged by the lack of objective diagnostic tools.
Source: wikipedia.org.
From symptoms to biomarkers: a new diagnostic paradigm
Historically, schizophrenia diagnosis has depended heavily on clinical interviews and behavioral observation, which can be subjective and difficult to standardize. BrainProbe shifts this paradigm by using imaging data to quantify abnormalities in brain structure and function — particularly in areas such as the insula and temporal lobe — that are linked to schizophrenia. The platform was trained on MRI scans from over 1,500 local participants collected since 2012 and has been in use at TVGH since 2019 for clinical evaluations.
Tracking brain aging and long-term disease progression
One of BrainProbe’s most innovative features is its ability to monitor brain aging and predict pathological changes over time. This function enables physicians not only to detect signs of schizophrenia but also to observe how brain structures evolve, helping tailor long-term treatment strategies.
Source: vghtpeimsc.tw.
As a clinical example, BrainProbe recently helped confirm schizophrenia in a patient exhibiting hallucinations and delusions by highlighting specific brain abnormalities.
Future expansion and regulatory review
Though currently accessible on a self-pay basis as part of a clinical trial at TVGH, BrainProbe is undergoing review by the Taiwan Food and Drug Administration. The system recently earned gold in the Advancements in Neurological Treatments category at the 2025 Edison Awards. Its development team, led by Dr. Albert Yang, is now working with international institutions to validate the platform’s effectiveness across different populations and ethnicities.
BrainProbe represents a transformative shift in psychiatric diagnostics, blending neuroscience with artificial intelligence to bring greater accuracy, consistency, and objectivity to schizophrenia assessment. As the platform seeks broader regulatory approval and global collaboration, it holds promise not only for improving diagnosis but also for advancing understanding of mental health on a worldwide scale.
